Skip to main content
OpenTrials
Completed

NCT Number: NCT03513744

Study Evaluating Growth and Tolerance of Infant Formula Containing HMOs

The primary objective of this clinical study is to investigate the suitability of an infant formula containing five different human milk oligosaccharides to support normal physical growth (evaluated per weight gain), in comparison with infant formula without human milk oligosaccharides, when the formula is fed as the sole source of nutrition.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

1 day–13 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Facharzt für Kinder und Jugendmedizin, Mannheim, Germany

Loading trial locations.

About this study

The main goal of the study is to investigate the suitability of an infant formula containing five different human milk oligosaccharides to support normal physical growth of term infants (evaluated per weight gain, body length and head circumference), in comparison with infant formula without human milk oligosaccharides, when the formula is fed exclusivly in the first four month of life. Additionally, a comparison of the two formula fed groups against a reference group with breastfed infants as well as the WHO growth standard reference tables will be performed. An assessment of safety and tolerability will be performed as well.

As a secondary out come of the study, we will examine the effect of the formula on the infant microbiome, as well as the HMO status of the mother's milk towards the microbial composition of the infant microbiome.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Singleton birth
  • Full-term infant (37 - 42 weeks of gestational age)
  • APGAR score of 9 or 10
  • Birth weight 2500 - 4500 g

Exclusion criteria

  • clinically significant condition/ disorder
  • Adverse maternal of fetal medical history that may influence growth/development of the subject or tolerance of the infant formula
  • readmission to hospital (except for hyperbilirubinemia)
  • allergy to cow's milk
  • participation in another study

Treatment and study plan

Human milk oligosaccharides

Dietary Supplement

mixture of five different human milk oligosaccharides

Primary outcomes

  1. assessment of body weight (in grams) of term infants

    Time frame: 4 month

    growth, assessed by body weight gain, of term infants from enrollment to 4 month of life

Secondary outcomes

  1. assessment of body length (in centimeter) of term infants

    Time frame: 4 month

    growth, assessed as body length, of term infants from enrollment to 4 month of life

  2. assessment of head circumference (in centimeter) of term infants

    Time frame: 4 month

    growth, assessed as head circumference, of term infants from enrollment to 4month of life

Other outcomes

  1. digestive tolerance

    Time frame: 4 month

    stool frequency and consistency

  2. influence of digestion

    Time frame: 4 month

    digestive tolerance parameters ( e.g. rigurgitation, flatulence) will be assessed

  3. influence on behaviour

    Time frame: 4 month

    behavior patterns (e.g.fussiness, cramps, awakings at night) will be assessed

  4. product compliance

    Time frame: 4 month

    intake of infant formula in ml

  5. morbidity

    Time frame: 4 month

    observation of illness

  6. stool microbiota

    Time frame: 4 month

    analysis of the fecal microbiota

  7. HMO composition in breast milk

    Time frame: 4 month

    analysis of HMO composition in mothers breastmilk in the breast-fed arm

Sponsors and collaborators

Lead sponsor

Jennewein Biotechnologie GmbH

Industry

Collaborators

  • Analyze & Realize

Registry information

Official study title

Evaluation of Nutritional Suitability and Tolerability of a Human Milk Oligosaccharide (HMO) Mix in Infant Formula for Term Infants

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
May 2, 2018
Registry last updated
Oct 16, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.